SEC Company Response from TECOGEN INC. (TGEN) (CIK 0001537435) (TGEN) — Nov 26, 2014
TECOGEN INC. (TGEN) (CIK 0001537435)
Date: Nov. 26, 2014 · CIK: 0001537435 · Accession: 0001537435-14-000094
AI Filing Summary & Sentiment
File numbers found in text: 333-199634
Referenced dates: November 4, 2014
Letter
Via EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Jay Ingram, Legal Branch Chief Re: Tecogen Inc. Registration Statement on Form S-3 Filed October 28, 2014 File No. 333-199634
Dear Staff:
We are submitting this letter on behalf of Tecogen Inc (the “Company” or “TGEN”) in response to comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) received by electronic mail dated November 4, 2014 relating to the Company’s Registration Statement on Form S-3 (File No. 333-199634) filed with the Commission on October 28, 2014 (the “Registration Statement”). The numbered paragraphs below correspond to the numbered comments in the Staff’s letter and the Staff’s comments are presented in bold.
Calculation of Registration Fee Table
1.
We note your disclosure in note (1) that the registration statement covers "such an indeterminate amount of common stock (with accompanying purchase rights, if any) . . .” [and] such an indeterminate amount of warrants, representing rights to purchase common stock .... " [emphasis added]. It is unclear if you are registering the offering of rights as a separate security in the fee table. Please revise accordingly or explain why you do not believe this is appropriate. If you are registering the offering of rights, please have counsel file an updated legality opinion covering the rights. For guidance, please refer to Question 116.16 of the Compliance and Disclosure Interpretations on Securities Act Forms available on the Commission’s web site.
We have deleted the reference to representation rights. This change will be reflected in our amended S-3.
* * *
In connection with responding to the Staff's comments, the Company hereby acknowledge and shall state in any future request for acceleration:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
We appreciate your comments and welcome the opportunity to discuss with you our responses provided above. Please call me at (781) 466-6403 or our attorney, Edwin Miller of Sullivan & Worcester LLP in Boston, at (617) 338-2447 if you have any questions or require additional information.Sincerely,
TECOGEN INC.
By: /s/ David A. Garrison
David A. Garrison
Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm TGN 2014 11 26 Corres - S-3 Comment Ltr ` November 26, 2014 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Jay Ingram, Legal Branch Chief Kamyar Daneshvar, Staff Attorney Re: Tecogen Inc. Registration Statement on Form S-3 Filed October 28, 2014 File No. 333-199634 Dear Staff: We are submitting this letter on behalf of Tecogen Inc (the “Company” or “TGEN”) in response to comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) received by electronic mail dated November 4, 2014 relating to the Company’s Registration Statement on Form S-3 (File No. 333-199634) filed with the Commission on October 28, 2014 (the “Registration Statement”). The numbered paragraphs below correspond to the numbered comments in the Staff’s letter and the Staff’s comments are presented in bold. Calculation of Registration Fee Table 1. We note your disclosure in note (1) that the registration statement covers "such an indeterminate amount of common stock (with accompanying purchase rights, if any) . . .” [and] such an indeterminate amount of warrants, representing rights to purchase common stock .... " [emphasis added]. It is unclear if you are registering the offering of rights as a separate security in the fee table. Please revise accordingly or explain why you do not believe this is appropriate. If you are registering the offering of rights, please have counsel file an updated legality opinion covering the rights. For guidance, please refer to Question 116.16 of the Compliance and Disclosure Interpretations on Securities Act Forms available on the Commission’s web site. We have deleted the reference to representation rights. This change will be reflected in our amended S-3. * * * In connection with responding to the Staff's comments, the Company hereby acknowledge and shall state in any future request for acceleration: • should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We appreciate your comments and welcome the opportunity to discuss with you our responses provided above. Please call me at (781) 466-6403 or our attorney, Edwin Miller of Sullivan & Worcester LLP in Boston, at (617) 338-2447 if you have any questions or require additional information.Sincerely, TECOGEN INC. By: /s/ David A. Garrison David A. Garrison Chief Financial Officer